Ahead of launching its first Android XR product, “Project Aura,” the new XREAL 1S glasses deliver some impressive new display upgrades, and for a lower price than its predecessor too. The XREAL 1S is ...

The latest spatial display glasses from Xreal can convert all in-display content to 3D, and with the Neo DisplayPort and battery hub, it can stream games from the Nintendo Switch 2. Here's what Xreal ...

Posts from this topic will be added to your daily email digest and your homepage feed. Despite the spec bump, the Xreal 1S are $50 cheaper than their predecessor. Despite the spec bump, the Xreal 1S ...

I started with CNET reviewing laptops in 2009. Now I explore wearable tech, VR/AR, tablets, gaming and future/emerging trends in our changing world. Other obsessions include magic, immersive theater, ...

XREAL has announced the XREAL 1S, a replacement for its XREAL One AR glasses. The 1S glasses come with higher-resolution displays, a wider field of view, and more improvements. XREAL also announced ...

The popularity of GLP-1 weight-loss drugs has seen a seismic shift in just over a year. Not long ago, they were primarily used for diabetes. But now, that’s changing. In some markets, such as the US, ...

The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies. The Centers for Medicare & Medicaid Services (CMS) on Tuesday announced the Better ...

Please provide your email address to receive an email when new articles are posted on . GLP-1s show benefit in patients with HF, regardless of obesity. GLP-1s raise heart rate, which is linked to ...

Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker. CagriSema is a ...

DEC 15 (Reuters) - A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while ...

Share on Pinterest Research suggests that GLP-1 drugs likely have little to no effect on risk for obesity-related cancers. Image credit: James Manning – PA Images/Getty Images In 2022, about 2.5 ...